100 years of Bacillus Calmette–Guérin immunotherapy: from cattle to COVID-19

N Lobo, NA Brooks, AR Zlotta, JD Cirillo… - Nature Reviews …, 2021 - nature.com
Abstract Bacillus Calmette–Guérin (BCG) is the most widely used vaccine worldwide and
has been used to prevent tuberculosis for a century. BCG also stimulates an anti-tumour …

The mechanism of action of BCG therapy for bladder cancer—a current perspective

G Redelman-Sidi, MS Glickman, BH Bochner - Nature reviews urology, 2014 - nature.com
Abstract Bacillus Calmette–Guérin (BCG) has been used to treat non-muscle-invasive
bladder cancer for more than 30 years. It is one of the most successful biotherapies for …

Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin …

RJ Sylvester, MA Brausi, WJ Kirkels, W Hoeltl… - European urology, 2010 - Elsevier
BACKGROUND: Intravesical chemotherapy and bacillus Calmette-Guérin (BCG) reduce the
recurrence rate in patients with stage Ta T1 urothelial bladder cancer; however, the benefit …

Predicting response to intravesical bacillus Calmette-Guérin immunotherapy: are we there yet? A systematic review

AM Kamat, R Li, MA O'Donnell, PC Black, M Roupret… - European urology, 2018 - Elsevier
Abstract Context Bacillus Calmette-Guérin (BCG) is currently the most effective intravesical
therapy for nonmuscle invasive bladder cancer, reducing not only recurrence rates but also …

Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer

A Böhle, S Brandau - The Journal of urology, 2003 - Elsevier
PURPOSE: Of all medical disciplines it is exclusively in urology in which immunotherapy for
cancer has an established position today with intravesical bacillus Calmette-Guerin (BCG) …

BCG in bladder cancer immunotherapy

S Jiang, G Redelman-Sidi - Cancers, 2022 - mdpi.com
Simple Summary Bacillus Calmette–Guérin (BCG), a live attenuated strain of Mycobacterium
bovis, is the most successful microbial immunotherapy of cancer in current use. Intravesical …

Changes in urinary cytokines and soluble intercellular adhesion molecule‐1 (ICAM‐1) in bladder cancer patients after Bacillus Calmette—Guérin (BCG) …

AM Jackson, AB Alexandroff, RW Kelly… - Clinical & …, 1995 - Wiley Online Library
Intravesical immunotherapy for carcinoma in situ of the bladder is arguably the most effective
form of tumour immunotherapy described to date. Following repeated instillations of BCG …

Role of urothelial cells in BCG immunotherapy for superficial bladder cancer

RFM Bevers, KH Kurth, DHJ Schamhart - British journal of cancer, 2004 - nature.com
Abstract Intravesical instillation of Bacillus Calmette-Guérin (BCG) is used for the treatment
of superficial bladder cancer, both to reduce the recurrence rate of bladder tumour and to …

Mechanisms of action of intravesical bacille Calmette-Guerin: local immune mechanisms

S Prescott, AM Jackson, SJ Hawkyard… - Clinical infectious …, 2000 - academic.oup.com
The local immune response to mycobacteria is complex, but mycobacterial antigen
presentation by phagocytes to T helper cells is the pivotal interaction. Bacille Calmette …

Urinary interleukin-2 may predict clinical outcome of intravesical bacillus Calmette-Guerin immunotherapy for carcinoma in situ of the bladder

E Watanabe, H Matsuyama, K Matsuda, C Ohmi… - Cancer immunology …, 2003 - Springer
Purpose The mechanism by which bacillus Calmette-Guérin (BCG) mediates antitumor
activity has not been clearly established. Specific cytokines in the urine after BCG …